New Cancer-Focused Biotech Forty Seven Inc. Selects Medidata to Accelerate Novel Immuno-Oncology R&D

NEW YORK–(BUSINESS WIRE)– Medidata
(NASDAQ:MDSO), the leading global provider of cloud-based solutions for
clinical research in life sciences, today announced that Forty
Seven Inc., a new biotechnology company specializing in cancer
immunotherapy, is powering two upcoming anti-cancer studies with the Medidata
Clinical Cloud^®.

Formed by Stanford University researchers in 2015 and backed by Sutter
Hill, Lightspeed, Clarus Ventures and Google’s GV,
the venture capital arm of Alphabet,
Inc., the Palo Alto, California-based biotech will leverage
Medidata’s industry-leading electronic data capture, management and
reporting system (Medidata
Rave^®) to advance therapies for cancers with highly unmet
medical needs.

“The idea to form Forty Seven Inc. stemmed from a growing passion for
science and pioneering breakthrough cancer solutions for patients.
That’s why we feel strongly about partnering with forward-thinking,
like-minded organizations such as Medidata,” said Karen Green, senior
director of clinical data management at Forty Seven. “As we continue to
scale our business and turn our research ideas into viable drug
candidates, Medidata’s flexible technology platform will provide us with
access to the data we need, when we need it—helping to advance our
pipeline of therapies and bring them to cancer patients who need new
treatment options.”

Forty Seven is named after the CD47 tumor cell protein that its lead
molecule, Hu5F9-G4—an experimental monoclonal cancer drug—aims to
attack. The biotech is embarking on a series of clinical trials to test
its safety and efficacy in solid tumor and blood cancers. As part of
these efforts, Forty Seven is using Rave in two of its upcoming Phase I
and Phase II trials to streamline study operations, improve data quality
and accessibility, and speed decision-making processes.

“We’re proud to partner with Forty Seven Inc., an innovative
organization that’s bringing together the best of academia and
cutting-edge science to power next-generation cancer research,” said
Medidata’s chief operating officer, Mike Capone. “With our cloud
platform and deep industry expertise, we’re arming Forty Seven’s R&D
teams with the technology, data and actionable insights they need to
make decisions safely and quickly, and charge ahead as an emerging
leader in the immuno-oncology space.”

Connect with Medidata

• Read our blog, Geeks
  Talk Clinical
• Tweet this: .@Stanford-born
  #biotech Forty Seven Inc. turns to @Medidata to power innovative
  #ImmunoOnc research: http://ow.ly/gyWW302FOA5 #tumor #CD47
• Follow us on Twitter: @Medidata
• Find us on LinkedIn

About Medidata

Medidata
is the leading global provider of cloud-based solutions for clinical
research in life sciences, transforming clinical development through its
advanced applications and intelligent data analytics. We are committed
to advancing the competitive and scientific goals of our life sciences
customers worldwide: more than 700 global pharmaceutical companies;
innovative biotech, diagnostic and device firms; leading academic
medical centers; and contract research organizations. Our
industry-leading technology platform, the Medidata Clinical Cloud^®,
is the primary technology solution powering clinical trials for 17 of
the world’s top 25 global pharmaceutical companies, bringing new levels
of productivity and quality to the clinical testing of promising medical
treatments, from study design and planning through execution, management
and reporting.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160728005425/en/